Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Astellas
Astellas
Astellas readies roxadustat for launch
EP Vantage
Wed, 09/15/21 - 10:37 am
Astellas
roxadustat
drug launches
Astellas reports fourth death in halted gene therapy trial
Pharmaforum
Tue, 09/14/21 - 10:59 am
Astellas
gene therapy
AT132
patient deaths
clinical trials
X-linked myotubular myopathy
More trouble for Astellas as AT132 gene therapy trial is halted again
Pharmaforum
Wed, 09/1/21 - 11:02 am
Astellas
gene therapy
AT132
clinical trials
X-linked myotubular myopathy
After FDA snub, EMA backs FibroGen, Astellas’ roxadustat
Pharmaforum
Fri, 08/20/21 - 10:51 am
Europe
FibroGen
Astellas
Evrenzo
anemia
chronic kidney disease
FDA Approvals Roundup: Kerendia, Padcev, Darzalex Faspro
RAPS.org
Thu, 07/15/21 - 12:34 pm
FDA
drug approvals
Bayer
Kerendia
Astellas
Padcev
Teva Pharmaceutical
ArmonAir RespiClick
Janssen
Darzalex Faspro
Pneumococcal Vaccine Snags Breakthrough Therapy Designation
BioSpace
Tue, 07/13/21 - 11:29 pm
Astellas
Affinivax
vaccines
pneumococcal disease
breakthrough therapy
Seagen, Astellas' Padcev snares full approval and expands into second-line treatment on path to blockbuster land
Fierce Pharma
Sat, 07/10/21 - 12:00 am
Astellas
Seagen
Padcev
FDA
bladder cancer
The big approvals still on the cards for 2021
EP Vantage
Thu, 06/17/21 - 11:00 am
FDA
drug approvals
Argenx
Novartis
AstraZeneca
Astellas
UCB Pharma
Ascendis Pharma
ChemoCentryx
Axsome Therapeutics
#ASCO21: Ahead of August PDUFA date, Astellas and Seagen sweeten Padcev pitch with new data
Endpoints
Thu, 05/20/21 - 12:16 pm
ASCO 2021
Astellas
Seagen
Padcev
FDA
urothelial cancer
Astellas quietly cuts Cytokinetics R&D pact as $450M-plus in biobucks goes up in smoke
Fierce Biotech
Mon, 05/3/21 - 10:51 am
Astellas
Cytokinetics
biobucks
Astellas takes $540M impairment charge over Audentes' gene therapy trial hold
Fierce Biotech
Tue, 04/27/21 - 10:47 am
Astellas
Audentes
AT132
gene therapy
Astellas innovation awards offer up ideas to ease cancer patients' pandemic burdens
Fierce Pharma
Tue, 04/20/21 - 07:36 pm
Astellas
cancer
innovation
Seagen gets August PDUFA for Padcev expansions
Endpoints
Mon, 04/19/21 - 10:25 pm
Seagen
FDA
Padcev
Astellas
Nearly a year after Audentes' gene therapy deaths, the trial continues. What happened remains a mystery
Endpoints
Wed, 04/14/21 - 09:37 am
Audentes
Astellas
gene therapy
clinical trials
Big pharma freshens up
EP Vantage
Fri, 04/9/21 - 10:35 am
Merck
Bristol Myers Squibb
Astellas
Novo Nordisk
AbbVie
Sanofi
Audentes CEO exits as Astellas rebrands a gene therapy buyout
BioPharma Dive
Thu, 04/1/21 - 11:01 am
Astellas
Audentes
gene therapy
M&A
Astellas Gene Therapies
Astellas gene therapy repairs damage in neurodegenerative disease models
Fierce Biotech
Wed, 03/31/21 - 11:08 pm
gene therapy
Astellas
Quethera
neurodegenerative disease
Astellas scores a pair of trial wins for menopausal hot flash med, raising the pitch of looming Bayer standoff
Endpoints
Fri, 02/19/21 - 10:27 am
Astellas
clinical trials
fezolinetant
menopause
hot flashes
Asco-GU – confirmatory Padcev trial throws a curveball
EP Vantage
Fri, 02/12/21 - 10:59 am
Astellas
Seagen
Padcev
bladder cancer
ASCO-GU
Aducanumab tops 2021’s biggest potential launches
EP Vantage
Mon, 01/18/21 - 01:04 pm
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »